Ane Alberdi1, Asier Aztiria2, Adrian Basarab3. 1. Mondragon University, Electronics and Computing Department, Goiru Kalea, 2, Arrasate 20500, Spain. Electronic address: aalberdiar@mondragon.edu. 2. Mondragon University, Electronics and Computing Department, Goiru Kalea, 2, Arrasate 20500, Spain. Electronic address: aaztiria@mondragon.edu. 3. Université de Toulouse, Institut de Recherche en Informatique de Toulouse, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5505, Université Paul Sabatier, 118 Route de Narbonne, 31062 Toulouse, France. Electronic address: adrian.basarab@irit.fr.
Abstract
INTRODUCTION: The number of Alzheimer's Disease (AD) patients is increasing with increased life expectancy and 115.4 million people are expected to be affected in 2050. Unfortunately, AD is commonly diagnosed too late, when irreversible damages have been caused in the patient. OBJECTIVE: An automatic, continuous and unobtrusive early AD detection method would be required to improve patients' life quality and avoid big healthcare costs. Thus, the objective of this survey is to review the multimodal signals that could be used in the development of such a system, emphasizing on the accuracy that they have shown up to date for AD detection. Some useful tools and specific issues towards this goal will also have to be reviewed. METHODS: An extensive literature review was performed following a specific search strategy, inclusion criteria, data extraction and quality assessment in the Inspec, Compendex and PubMed databases. RESULTS: This work reviews the extensive list of psychological, physiological, behavioural and cognitive measurements that could be used for AD detection. The most promising measurements seem to be magnetic resonance imaging (MRI) for AD vs control (CTL) discrimination with an 98.95% accuracy, while electroencephalogram (EEG) shows the best results for mild cognitive impairment (MCI) vs CTL (97.88%) and MCI vs AD distinction (94.05%). Available physiological and behavioural AD datasets are listed, as well as medical imaging analysis steps and neuroimaging processing toolboxes. Some issues such as "label noise" and multi-site data are discussed. CONCLUSIONS: The development of an unobtrusive and transparent AD detection system should be based on a multimodal system in order to take full advantage of all kinds of symptoms, detect even the smallest changes and combine them, so as to detect AD as early as possible. Such a multimodal system might probably be based on physiological monitoring of MRI or EEG, as well as behavioural measurements like the ones proposed along the article. The mentioned AD datasets and image processing toolboxes are available for their use towards this goal. Issues like "label noise" and multi-site neuroimaging incompatibilities may also have to be overcome, but methods for this purpose are already available.
INTRODUCTION: The number of Alzheimer's Disease (AD) patients is increasing with increased life expectancy and 115.4 million people are expected to be affected in 2050. Unfortunately, AD is commonly diagnosed too late, when irreversible damages have been caused in the patient. OBJECTIVE: An automatic, continuous and unobtrusive early AD detection method would be required to improve patients' life quality and avoid big healthcare costs. Thus, the objective of this survey is to review the multimodal signals that could be used in the development of such a system, emphasizing on the accuracy that they have shown up to date for AD detection. Some useful tools and specific issues towards this goal will also have to be reviewed. METHODS: An extensive literature review was performed following a specific search strategy, inclusion criteria, data extraction and quality assessment in the Inspec, Compendex and PubMed databases. RESULTS: This work reviews the extensive list of psychological, physiological, behavioural and cognitive measurements that could be used for AD detection. The most promising measurements seem to be magnetic resonance imaging (MRI) for AD vs control (CTL) discrimination with an 98.95% accuracy, while electroencephalogram (EEG) shows the best results for mild cognitive impairment (MCI) vs CTL (97.88%) and MCI vs AD distinction (94.05%). Available physiological and behavioural AD datasets are listed, as well as medical imaging analysis steps and neuroimaging processing toolboxes. Some issues such as "label noise" and multi-site data are discussed. CONCLUSIONS: The development of an unobtrusive and transparent AD detection system should be based on a multimodal system in order to take full advantage of all kinds of symptoms, detect even the smallest changes and combine them, so as to detect AD as early as possible. Such a multimodal system might probably be based on physiological monitoring of MRI or EEG, as well as behavioural measurements like the ones proposed along the article. The mentioned AD datasets and image processing toolboxes are available for their use towards this goal. Issues like "label noise" and multi-site neuroimaging incompatibilities may also have to be overcome, but methods for this purpose are already available.
Authors: Jeremiah K H Lim; Qiao-Xin Li; Zheng He; Algis J Vingrys; Vickie H Y Wong; Nicolas Currier; Jamie Mullen; Bang V Bui; Christine T O Nguyen Journal: Front Neurosci Date: 2016-11-17 Impact factor: 4.677
Authors: Behnaz Ghoraani; Lillian N Boettcher; Murtadha D Hssayeni; Amie Rosenfeld; Magdalena I Tolea; James E Galvin Journal: Biomed Signal Process Control Date: 2020-10-16 Impact factor: 3.880
Authors: William Perry; Laura Lacritz; Tresa Roebuck-Spencer; Cheryl Silver; Robert L Denney; John Meyers; Charles E McConnel; Neil Pliskin; Deb Adler; Christopher Alban; Mark Bondi; Michelle Braun; Xavier Cagigas; Morgan Daven; Lisa Drozdick; Norman L Foster; Ula Hwang; Laurie Ivey; Grant Iverson; Joel Kramer; Melinda Lantz; Lisa Latts; Shari M Ling; Ana Maria Lopez; Michael Malone; Lori Martin-Plank; Katie Maslow; Don Melady; Melissa Messer; Randi Most; Margaret P Norris; David Shafer; Nina Silverberg; Colin M Thomas; Laura Thornhill; Jean Tsai; Nirav Vakharia; Martin Waters; Tamara Golden Journal: Arch Clin Neuropsychol Date: 2018-09-01 Impact factor: 2.813
Authors: Lillian N Boettcher; Murtadha Hssayeni; Amie Rosenfeld; Magdalena I Tolea; James E Galvin; Behnaz Ghoraani Journal: Annu Int Conf IEEE Eng Med Biol Soc Date: 2020-07